Home / Companies / Cerevel Therapeutics Holdings, Inc. / 16 Feb 2024
Cerevel Therapeutics Holdings, Inc.: meeting of 16 Feb 2024
Votes reported on Form N-PX, item by item
295 Form N-PX filers reported votes at the Cerevel Therapeutics Holdings, Inc. meeting of 16 Feb 2024. Their records fall into 3 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.
foragainstabstain, withhold or otheramber tick: the portion cast against management
Items
SECTION 14A SAY-ON-PAY VOTESIssuer
Advisory vote on executive pay (say-on-pay)
409 vote records from 287 filers. 212 of the 273 filers that marked the item either way voted against management. 14 filers reported this item without a management mark.
One filer reported a share count too large to be the holding described. That figure is left out of the share split below; the count of filers includes it. How that is decided
EXTRAORDINARY TRANSACTIONSIssuer
EXTRAORDINARY TRANSACTIONS: management items
Management items in this category are shown together; filers word and number them differently.
161 vote records from 95 filers. 0 of the 95 filers that marked the item either way voted against management.
CORPORATE GOVERNANCEIssuer
CORPORATE GOVERNANCE: management items
Management items in this category are shown together; filers word and number them differently.
210 vote records from 113 filers. 17 of the 113 filers that marked the item either way voted against management.
How the largest families voted
| Family | 1. Say-on-pay |
|---|---|
| Vanguard | Against * |
| BlackRock and iShares | Against * |
| Fidelity | Against * |
| Dimensional | Against * |
| State Street and SPDR | For |
| American Century | Against * |
| Invesco | Against * |
| Equitable | Against * |
| Charles Schwab | Against * |
| Nuveen and TIAA | Against * |
| ProShares and ProFunds | Against * |
| John Hancock and Manulife | Against * |
| Morgan Stanley, Eaton Vance and Calvert | Against * |
| J.P. Morgan | Against * |
| Goldman Sachs | Against * |
| PGIM and Prudential | For |
| Jackson National funds | Against * |
| Northern Trust and FlexShares | Against * |
| SEI | Against * |
| T. Rowe Price | Against * |
| Lincoln Financial | For |
| Voya | Abstain or withhold * |
| Nationwide | Against * |
| Victory Capital | Against * |
| Brighthouse Funds | Against * |
| Guggenheim and Rydex | Against * |
| Columbia Threadneedle | Against * |
| BNY Mellon | Against * |
| Principal | Against * |
| Capital Group and American Funds | Against * |
| Pacific Life funds | Against * |
| Global X | Against * |
| Transamerica | Against * |
| AllianceBernstein | Against * |
| DWS | Against * |
| PIMCO | Against * |
| Harbor Funds | For |
| Virtus | For |
| Janus Henderson | Against * |
| Neuberger Berman | For |
* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.
Questions
How did large funds vote at the Cerevel Therapeutics Holdings, Inc. meeting?
295 Form N-PX filers reported votes at the meeting of 16 Feb 2024. On say-on-pay, 212 of 273 voted against management (77.7%). The family table lists each of the largest families item by item.
Is this the meeting result?
No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Cerevel Therapeutics Holdings, Inc. on Form 8-K.
Why are director elections shown as counts only?
Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.
Every meeting on file for Cerevel Therapeutics Holdings, Inc.
Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Cerevel Therapeutics Holdings, Inc. with a meeting date within three days of 16 Feb 2024. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.